Media Contact
Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday:
- Andrea Greif
Senior Director, Communications
(914) 821-8958
andrea.greif@lls.org
Man & Woman of the Year Sets New Fundraising Record
Rye Brook, NY (July 6, 2016) – What happens when community leaders across the country devote 10 weeks of their time and energy to raise funds to find cures for cancer? Records are broken. The Leukemia & Lymphoma Society’s (LLS) unique Man & Woman of the Year national campaign winners raised a record-breaking combined total of more than $800,000 for LLS’s goal to find cures for blood cancers and ens...
Peter Brock Elected Chair of LLS Board of Directors
Rye Brook, N.Y. (June 28, 2016) – Real estate developer Peter Brock will become chair of The Leukemia & Lymphoma Society’s (LLS) national board of directors effective July 1, 2016. His term will run through June 30, 2018. He has served as the board’s secretary/treasurer since July 1, 2015. Brock has decades of experience in developing commercial real estate throughout the U.S. He is currently a partner i...
Dr. Renzo Canetta Elected to LLS National Board of Directors
Rye Brook, N.Y. (June 28, 2016) – Renzo Canetta, M.D., former vice president of Oncology Global Clinical Research and of Global Regulatory Oncology Research Policy at Bristol-Myers Squibb (BMS), has been elected to the national board of directors of The Leukemia & Lymphoma Society (LLS), effective July 1, 2016. His term will run through June 30, 2019 and is subject to renewal. Dr. Canetta has more than ...
Kathleen Meriwether Elected to LLS National Board of Directors
Rye Brook, N.Y. (June 28, 2016) – Kathleen Meriwether, Americas Life Sciences Leader for Ernst & Young LLP’s (EY) Fraud Investigation & Dispute Services practice, has been elected to the national board of directors of The Leukemia & Lymphoma Society (LLS), effective July 1, 2016. Her term will run through June 30, 2019 and is subject to renewal. Meriwether, specializes in assisting health sciences ...
LLS and ASH Announce Collaboration Against Deadly Form of Leukemia
Rye Brook, NY; Washington, DC – June 20, 2016 - The Leukemia & Lymphoma Society (LLS) and the American Society of Hematology (ASH) are teaming up to raise awareness and provide education about the need for new treatments for acute myeloid leukemia (AML), one of the most deadly blood cancers that has not seen a change in the standard of care for more than 40 years. AML is a complex group of approximately 20 d...
New Research: Americans of Every Political Stripe are Unified in Support of Vice President Biden’s Moonshot to End Cancer
Rye Brook, NY, June 1, 2016 – While divisiveness rules many issues, there is strong agreement among Americans of different political persuasions when it comes to investing in the fight against cancer. According to a new survey, Finding Cancer Cures, there is widespread support for the Moonshot to End Cancer initiative President Obama launched this year, as 82 percent of Americans polled want the next presiden...
Subaru and LLS Celebrate Gestures of Hope for Subaru Love Promise
Rye Brook, NY (May 31, 2016) – Subaru of America and The Leukemia & Lymphoma Society (LLS) announced a collaboration to provide much needed support and “warmth” to patients fighting cancer and their families in communities across the country. During Subaru Loves to Care month this June, LLS and participating Subaru retailers across the country together will provide blankets and messages of hope to ...
LLS Applauds Approval of New Therapy for CLL Patients
Rye Brook, NY – April 12, 2016 – The approval of a new therapy for patients with a high-risk form of chronic lymphocytic leukemia (CLL) is welcome news for patients for whom there have been few other options, The Leukemia & Lymphoma Society (LLS) said today. The U.S. Food and Drug Administration has approved venetoclax (Venclexta ®) to treat patients with a rare subset of CLL in which a piece of chromosom...